Biogen Inc. · BIIB · Next earnings

Biogen Inc. reports Friday, Feb 5, 2027

BIIB reports before market open with consensus EPS at $2.85 and revenue at $2.61B. Last quarter: Biogen’s Q3 growth broadened beyond legacy MS franchise

Reports Before market open93 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.85 Calendar consensus
Consensus revenue $2.61B Calendar consensus
Report date Feb 5, 2027 Friday, date estimated
Session Before market open 93 days away

Where BIIB left off: FY2026 Q3

Full report

Biogen’s Q3 growth broadened beyond legacy MS franchise

EPS surprise +31.7% Reported $2.62 vs $1.99
Revenue surprise +6.4% Reported $2.80B vs $2.63B
Stock move -3.4% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised full-year 2026 non-GAAP diluted EPS guidance, according to the supplied transcript analysis.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Integration and financing effects from the Apellis acquisition.
  • Dependence on upcoming clinical data for litifilimab, felzartamab, and other pipeline assets.
  • Formulary and pricing pressure on VUMERITY and other Part D products.
  • Pricing and reimbursement uncertainty for felzartamab, iClick/LEQEMBI, and new indications.

Questions analysts left open

  • Confidence in Phase III outcomes for litifilimab and felzartamab, including differences in SLE study baselines.
  • Whether SYFOVRE injection growth reflects underlying demand or lower free-drug use.
  • The effect of SKYCLARYS inventory buildup and subsequent drawdown.
  • Capital allocation between commercial investment and research and development.
  • Pricing strategy for ZURZUVAE outside the United States.

Ask FN2 about BIIB next report

Transcript, numbers and history already loaded
What should I watch for in BIIB's next earnings report?How did BIIB guide last quarter, and is consensus above or below that?Give me the bull and bear case going into BIIB earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the BIIB recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent BIIB quarters

All BIIB earnings
-3.4%FY2026 Q3+1.8%FY2026 Q2+6.0%FY2026 Q1+1.2%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.